# colorectal cancer - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 34518
- Completion tokens: 11640
- Reasoning tokens: 0
- Total tokens: 46158
- API requests reported: 4
- Elapsed seconds: 267.413
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: Anthropic

---
# Transcriptomic Interpretation: Prognostic Gene Signature in Colorectal Cancer

## 1. Overall Biological Interpretation

The prognostic transcriptomic signature in colorectal tumor tissue reveals a conflict between two fundamental cellular programs: **mitochondrial metabolic fitness** versus **tumor microenvironment remodeling and immune evasion**. 

Protective genes (HR < 1, associated with better overall survival) are dominated by mitochondrial respiratory chain components (NDUFA9, ATP23, ATP5B, COA3, TIMM13), enzymes of intermediary metabolism (CS, ACSS2, ASL, MCCC2, ILVBL), and differentiation markers (CDX2, LGALS4). This suggests that tumors retaining oxidative metabolic capacity and epithelial differentiation confer better prognosis.

Conversely, risk-associated genes (HR > 1, predicting worse survival) include stromal/extracellular matrix remodeling factors (INHBB, SCARA3, ITGBL1, ADAMTS18), oncogenic signaling nodes (AKT3, ABL2), epithelial-mesenchymal transition regulators (ZEB1-AS1, MIR31HG), and cytoskeletal reorganization machinery (TPM4, NIN, MYO5B). This points to a dedifferentiated, invasive, and metabolically reprogrammed tumor state.

The signature does not simply reflect tumor proliferation. Instead, it captures **metabolic-stromal axis reprogramming**—tumors that shift from oxidative metabolism toward glycolytic/mesenchymal programs exhibit worse outcomes, consistent with the Warburg effect and aggressive colorectal cancer biology.

---

## 2. Core Biological Programs

### **Program 1: Mitochondrial Respiratory Function and Metabolic Competence**

**Direction:** Protective (HR < 1)  
**Major supporting genes:** NDUFA9 (HR=0.69, FDR=0.0086), ATP23 (HR=0.69, FDR=0.0066), CS (HR=0.75, FDR=0.039), TIMM13 (HR=0.75, FDR=0.039), COA3, ATP5B, ATP5G1, MCCC2 (HR=0.74, FDR=0.028)  
**Pathway:** Reactome: Respiratory electron transport (R-HSA-611105), TCA cycle (R-HSA-71403)  
**Interpretation:** Multiple genes encoding mitochondrial respiratory chain subunits (Complex I: NDUFA9; Complex IV assembly: COA3, ATP23; ATP synthase: ATP5B, ATP5G1) and TCA cycle enzymes (CS, citrate synthase) are independently protective. NDUFA9 is a core Complex I subunit; ATP23 is a mitochondrial protease required for ATP synthase assembly. CS catalyzes the first step of the TCA cycle. TIMM13 is a mitochondrial import component. These genes collectively indicate **intact oxidative phosphorylation**. Tumors maintaining mitochondrial function may be less glycolytic, less hypoxic, and less prone to metastatic dissemination. The protective effect is consistent across multiple independent mitochondrial components, suggesting this is a program-level rather than gene-specific effect.  
**Evidence strength:** Strong. Eight independent mitochondrial genes converge on this program, with FDR < 0.05 for most. GTEx confirms high expression of these genes in normal colon tissue. Limitation: no external cohort validation; mitochondrial gene expression may partially reflect tumor cellularity or stromal dilution.

---

### **Program 2: Stromal Activation and Extracellular Matrix Remodeling**

**Direction:** Risk-associated (HR > 1)  
**Major supporting genes:** INHBB (HR=1.43, FDR=0.0011), SCARA3 (HR=1.38, FDR=0.0024), ITGBL1 (HR=1.30, FDR=0.031), ADAMTS18, DCBLD2 (HR=1.41, FDR=0.0086)  
**Pathway:** Reactome: Extracellular matrix organization (R-HSA-1474244); GO: Extracellular region (GO:0005576)  
**Interpretation:** INHBB (inhibin beta B) is the most significant risk gene and encodes a TGF-β superfamily ligand implicated in tumor-stroma crosstalk and cancer-associated fibroblast activation. SCARA3 (scavenger receptor) and DCBLD2 (discoidin, CUB and LCCL domain-containing 2) are stromal/endothelial markers. ITGBL1 and ADAMTS18 are extracellular matrix proteins. These genes do not simply reflect the presence of stroma; rather, they indicate **active stromal remodeling and paracrine signaling** that supports tumor invasion and immune exclusion. Europe PMC literature (PMID 41992239) directly links high INHBB expression to poor prognosis and malignant phenotypes in colorectal cancer. The convergence of multiple ECM and secreted factors points to a tumor-microenvironment co-evolution program.  
**Evidence strength:** Strong. INHBB has the strongest statistical effect (FDR=0.001) and direct literature support in CRC. Multiple ECM genes converge. Limitation: stromal gene expression may be confounded by tumor purity; single-cell or spatial data would better resolve tumor vs. stromal origin.

---

### **Program 3: PI3K/AKT Oncogenic Signaling**

**Direction:** Risk-associated (HR > 1)  
**Major supporting genes:** AKT3 (HR=1.32, FDR=0.039), ABL2 (HR=1.30, FDR=0.028), PTPN14 (HR=1.36, FDR=0.025), LRRC8A (HR=1.38, FDR=0.025)  
**Pathway:** KEGG: PI3K-Akt signaling pathway (hsa04151); Reactome: Signaling by receptor tyrosine kinases (R-HSA-9006934)  
**Interpretation:** AKT3 is a paralog of AKT1/2 in the PI3K/AKT pathway, a central oncogenic axis in colorectal cancer. ABL2 (ABL-related gene) is a non-receptor tyrosine kinase involved in cytoskeletal remodeling and cell migration. PTPN14 is a protein tyrosine phosphatase with tumor-suppressive roles in Hippo signaling, but its high expression here may reflect pathway feedback or isoform-specific effects. LRRC8A is a volume-regulated anion channel component but has been linked to AKT signaling modulation. The co-occurrence of AKT3 and ABL2 suggests **coordinated activation of growth and motility signaling**. AKT3 is less frequently studied than AKT1 but has been implicated in therapy resistance and metastasis in multiple cancers. The risk association suggests this pathway drives aggressive tumor behavior.  
**Evidence strength:** Moderate. AKT3 and ABL2 are well-established oncogenes, but the statistical evidence here is modest (FDR ~0.03–0.04). PTPN14's role is context-dependent. No direct CRC literature for AKT3 prognosis was retrieved, though PI3K/AKT pathway activation is canonical in CRC. Limitation: pathway-level activation is better assessed by phosphoproteomic or downstream target gene sets than individual mRNA levels.

---

### **Program 4: Epithelial Differentiation and Intestinal Identity**

**Direction:** Protective (HR < 1)  
**Major supporting genes:** CDX2 (HR=0.75, FDR=0.036), LGALS4 (galectin-4), MYB (HR=0.77, FDR=0.019), PRR15L (HR=0.80, FDR=0.039)  
**Pathway:** GO: Epithelial cell differentiation (GO:0030855); Reactome: Intestinal immune network for IgA production  
**Interpretation:** CDX2 is a master transcription factor for intestinal epithelial differentiation and a well-established favorable prognostic marker in CRC. PubMed literature (PMID 30631044) confirms CDX2 inhibits CRC proliferation by transactivating Wnt antagonists (GSK-3β, Axin2). LGALS4 (galectin-4) is an intestinal epithelial lectin marking differentiated colonocytes. MYB is a transcription factor controlling hematopoietic and epithelial lineage programs. PRR15L is a less-characterized gene but has been linked to epithelial differentiation. These genes collectively indicate **retention of intestinal epithelial identity**. Tumors that maintain differentiation are typically less invasive and more chemosensitive. Loss of CDX2 is a hallmark of poorly differentiated, aggressive CRC.  
**Evidence strength:** Strong. CDX2 is a validated CRC prognostic marker with direct mechanistic literature. LGALS4 is a known differentiation marker. MYB adds independent support. Limitation: CDX2 expression alone does not capture post-transcriptional or epigenetic silencing; protein-level validation is preferable.

---

### **Program 5: Epithelial-Mesenchymal Transition (EMT) and Long Non-Coding RNA Regulation**

**Direction:** Risk-associated (HR > 1)  
**Major supporting genes:** ZEB1-AS1 (HR=1.37, FDR=0.0086), MIR31HG (HR=1.31, FDR=0.0066), NR2F1-AS1 (HR=1.31, FDR=0.036), TPM4 (HR=1.36, FDR=0.0089)  
**Pathway:** Hallmark: Epithelial-Mesenchymal Transition; GO: Regulation of cell migration (GO:0030334)  
**Interpretation:** ZEB1-AS1 is an antisense lncRNA to ZEB1, a master EMT transcription factor. MIR31HG hosts MIR31, a context-dependent oncomiR or tumor suppressor. NR2F1-AS1 regulates NR2F1 (COUP-TFII), a transcription factor linked to stemness and EMT. TPM4 (tropomyosin 4) is a cytoskeletal component enriched in mesenchymal and contractile cells. These genes do not directly encode EMT transcription factors (ZEB1, SNAI1, TWIST1), but their **regulatory lncRNAs and downstream cytoskeletal effectors** suggest an active EMT program. EMT in CRC is associated with metastasis, chemoresistance, and immune evasion. The convergence of multiple lncRNAs suggests post-transcriptional control is a key layer of EMT regulation in this cohort.  
**Evidence strength:** Moderate. ZEB1-AS1 and MIR31HG are statistically strong (FDR < 0.01), and lncRNA-EMT links are established in cancer biology. However, lncRNA mechanisms are often cell-type and context-specific, and direct functional validation in CRC is limited for these specific transcripts. TPM4's role in EMT is indirect. Limitation: lncRNA expression does not always correlate with target gene activity; mechanistic validation required.

---

## Summary

This 100-gene prognostic signature in colorectal cancer captures a **metabolic-stromal-differentiation axis**. Tumors retaining mitochondrial oxidative metabolism and epithelial differentiation (Programs 1 and 4) have better outcomes, while those exhibiting stromal remodeling, oncogenic signaling, and EMT (Programs 2, 3, and 5) predict worse survival. The biological coherence across multiple independent genes within each program, combined with literature and pathway support, provides robust evidence for these interpretations. Key limitations include the lack of external cohort validation, potential confounding by tumor purity, and the need for protein-level and functional validation of mRNA-based findings.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=41, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
